SynthesisBMC pharmacology & toxicology2025
Exploring the efficacy of intranasal oxytocin (OXT) for anxiety and stress-related disorders through functional magnetic resonance imaging (fMRI) study: a systematic review.
Synthesis in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Oxytocin preserves excitatory responsiveness of VTA dopaminergic neurons in PTSD model rats.IBRO neuroscience reports · 2026Article
- Responses to Aversive Acoustic Stimuli in Posttraumatic Stress Disorder: Moderation by the Presence of a Service Dog in Training.Psychophysiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnxiety and stress-related disorders are associated with abnormal neural reactivity and connectivity, particularly in the amygdala and prefrontal regions. Intranasal oxytocin (OXT) has emerged as a potential modulator of these neural circuits, but evidence for its clinical efficacy remains mixed. This systematic review aims to evaluate the effects of intranasal OXT on brain function in anxiety and stress-related disorders using functional Magnetic Resonance Imaging (fMRI) studies.
methodsFour electronic databases (PubMed, Scopus, Web of Science, and Cochrane central) were queried for English publications up to February 2025. The search involved utilizing various keyword combinations, including “Stress” OR “Anxiety” AND " Oxytocin”. No restrictions were imposed on these terms or any synonyms incorporated into the search approach. The Cochrane Risk of Bias Tool for randomized controlled trials (RCTs) was employed to assess the quality of the included studies.
resultsWe included 16 RCTs out of a total of 996 studies in this review. The findings were categorized according to specific disorder types: participants with trauma-related PTSD (n = 11), those diagnosed with social anxiety disorder (SAD) (n = 5). OXT showed promise as a treatment for conditions associated with stress and anxiety. In PTSD patients, OXT improved functional connectivity (FC) between the amygdala and cortical areas and altered amygdala reactivity, effects that were influenced by factors such as sex, symptom severity, and history of trauma or anxiety. For SAD, OXT enhanced amygdala-prefrontal cortex connectivity and decreased reactivity between the insula and amygdala. Additionally, differences between males and females in these stress related and anxiety disorders appear to affect how OXT exerts its effects.
conclusionsThis review highlights the potential of intranasal OXT as a promising treatment for stress related and anxiety disorders, showing its ability to modulate key brain regions involved in emotion regulation and cognition, such as the amygdala, prefrontal cortex, insula, and striatum. While further research is needed to optimize its use, intranasal OXT offers a viable biological-based therapy, with effects that may differ between sexes. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.